{"url_path":"/sec/cik-0001178879/8-k/2026-04-27/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1178879/0001140361-26-016968-index.html","accession_number":"0001140361-26-016968","cik":"0001178879","ticker":null,"issuer_name":"AMICUS THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1178879/0001140361-26-016968-index.html","primary_entity_key":"0001178879","primary_entity_name":"AMICUS THERAPEUTICS, INC."},"word_count":205,"has_tables":true,"body_markdown":"Item 3.01\n\nNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\n\n \n\nThe disclosures under the Introductory Note are incorporated herein by reference.\n\n \n\nOn April 27, 2026, the Company (i) notified the Nasdaq Global Select Market (“Nasdaq”) of the consummation\nof the Merger and its intent to remove all Company Common Stock from Nasdaq and (ii) requested that Nasdaq (A) halt trading of Company Common Stock effective before the opening of trading on and continuing through April 27, 2026, and (B) file with\nthe SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Company Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange\n\nAct”). As a result, Company Common Stock will be suspended from trading on Nasdaq on April 28, 2026. Following the effectiveness of such Form 25, the Company intends to file with the SEC a Certification and Notice of Termination of\nRegistration on Form 15 under the Exchange Act, requesting the termination of registration of the Company Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of\nthe Exchange Act."}